Table 4.

Univariate and multivariate analysis of risk factor for infectious and non-infectious pulmonary toxicity

	Infectious			Non-infectious
	SHR	95% CI	P-value	SHR	95% CI	P-value
Univariate analysis
Group
Reduced dose rate group	1 (ref)			1 (ref)
Conventional dose rate group	1.77	0.81–3.85	0.153	4.06	0.90–18.28	0.068
Total dose (Gy)	1.38	1.02–1.87	0.038	0.83	0.55–1.26	0.381
Daily dose (Gy)
Daily dose < 3	1 (ref)			1 (ref)
Daily dose ≥3	0.52	0.25–1.10	0.087	0.68	0.37–1.22	0.201
Women	1.22	0.64–2.34	0.545	1.10	0.35–3.44	0.871
Age at TBI (year)	1.00	0.98–1.02	0.854	0.99	0.96–1.02	0.486
Cancer type
ALL	1 (ref)			1 (ref)
AML	1.69	0.87–3.31	0.124	1.40	0.30–6.57	0.668
Others	1.22	0.48–3.09	0.671	1.26	0.36–4.44	0.718
Unrelated donor	1.30	0.68–2.48	0.436	0.98	0.34–2.85	0.971
Conditioning regimen
Cyclophosphamide	1 (ref)			1 (ref)
Cyclophosphamide + other*	1.65	0.65–4.20	0.290	Cannot be calculated	Cannot be calculated	0.921
Others†	0.80	0.29–2.19	0.659	Cannot be calculated	Cannot be calculated	0.925
Prior chemotherapy regimens
1	1 (ref)			1 (ref)
2	0.60	0.27–1.35	0.219	0.45	0.07–2.97	0.405
≥ 3	1.25	0.60–2.60	0.551	2.20	0.42–11.42	0.349
Multivariate analysis
Group
Reduced dose rate group	1 (ref)
Conventional dose rate group	2.38	1.02–5.54	0.045
Total dose (Gy)	1.40	1.07–1.85	0.016
Daily dose (Gy)	0.24	0.07–0.83	0.025
Cancer type
ALL	1 (ref)
AML	1.69	0.83–3.42	0.146
Others	1.41	0.56–3.52	0.463

*other: cytarabine, fludarabine, etoposide † others: cytarabine/fludaraibine, busulfan/fludarabine/etoposide, melphalan, melphalan/fludarabine, thiotepa